Full Year 2023 Investor Presentation

90 Investor presentation Full year 2023 Novo Nordisk has a value market share of ~19% in the global human growth disorder market Novo Nordisk value market share in the competitive hGH market A portfolio offering across markets Value MS% SogroyaⓇ strategy 19% 36% 37% 36% 33% 30% 22% 18% 16% 14% 14% 14% SOGROYAⓇ somapacitan 18% 12% 13% 14% 15% 16% • 38% 36% 36% 37% 37% 41% H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 H2 2023 Novo Nordisk Company A Company B Others norditropin® (somatropin) injection • Once-weekly efficacious treatment on par with NorditropinⓇ Simple and easy-to-use device Phase 3 trials toward broad range of indications (e.g. SGA, Turner, Noonan, ISS) to expand the market Approved for GHD in US, EU and Japan NorditropinⓇ strategy Apply a market-fit approach to support specific markets and patient groups Broad label across eight indications hGH: Human growth hormone; SGA: Small for gestational age, ISS; Idiopathic short stature Note: Due to contractual obligations competitor names are not disclosed. Company A and B represent actual companies; Market values are based on the list prices Source: IQVIA, MAT Nov 2023 Novo NordiskⓇ

View entire presentation